1. Al-Momani E, Zlatopolskiy BD, Solbach C, Reske SN, Machulla H-J. Synthesis of 15-(4-[131I]iodophenyl)pentadecanoic acid (p-IPPA) via tin-precursor using Chloramine-T as an oxidant. J Radioanal Nucl Chem 2010; 286:231–234.
  2. Barbaro D, Verburg FA, Luster M, Reiners C, Rubello D. ALARA in rhTSH-stimulated post-surgical thyroid remnant ablation: what is the lowest reasonably achievable activity? Eur J Nucl Med Mol Imaging 2010; 37:1251-1254.
  3. Bischoff M, Bischoff G, Buck A, Von Baer A, Pauls S, Scheffold F, Schultheiss M, Gebhard F, Reske SN. Integrated FDG-PET-CT: its role in the assessment of bone and soft tissue tumors. Arch Orthop Trauma Surg 2010; 130:819-827.
  4. Bombardieri E, Giammarile F, Aktolun C, Baum RP, Bischof Delaloye A, Maffioli L, Moncayo R, Mortelmans L, Pepe G, Reske SN, Castellani MR, Chiti A. 131I/ 123I-Metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010; 37:2436-2446.
  5. Diessl S, Verburg FA, Luster M, Reiners C. E-learning in medicine with nuclear medicine as an example. Nuklearmedizin 2010; 49:125-127.
  6. Diessl S, Verburg FA, Hoernlein A, Schumann M, Luster M, Reiners C. Evaluation of an internet-based e-learning module to introduce nuclear medicine to medical students: a feasibility study. Nucl Med Commun 2010; 31:1063-1067.
  7. Dietlein M, Luster M, Reiners C. Nuclear medicine therapy of differentiated thyroid cancer: Status quo. Onkologe 2010; 16:678-689.
  8. Dietlein M, Kobe C, Luster M. Differentiated Thyroid Cancer: New Concept of Radioiodine Ablation. Der Nuklearmediziner 2010; 33:203-213.
  9. Dueren C, Dietlein M, Luster M, Plenzig F, Steinke R, Grimm J, Groth P, Eichhorn W, Reiners C. The use of thyrogen in the treatment of differentiated thyroid carcinoma: an intraindividual comparison of clinical effects and implications of daily life. Exp Clin Endocrinol Diabetes 2010; 118:513-519.
  10. Freudenmann RW, Kölle M, Huwe A, Luster M, Reske SN, Huber M, Lepping P, Wolf RC, Schonfeldt-Lecuona C. Delusional infestation: neural correlates and antipsychotic therapy investigated by multimodal neuroimaging. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:1215-1222.
  11. Greiner J, Küfer R, Reske SN, Martin V, Döhner H, Ringhoffer M. Metronomic treatment with low-dose trofosfamide leads to a long-term remission in a patient with docetaxel-refractory advanced metastatic prostate cancer. Case Report Med. 2010; 395720:1-4.
  12. Hillenbrand A, Varhaug JE, Brauckhoff M, Pandev R, Haufe S, Dotzenrath C, Koberle R, Hoffmann R, Klein G, Kadmon M, Negele T, Hagieva T, Henne-Bruns D, Luster M, Weber T. Familial nonmedullary thyroid carcinoma-clinical relevance and prognosis. A European multicenter study. ESES Vienna presentation. Langenbecks Arch Surg 2010; 395:851-858.
  13. Hindorf C, Glatting G, Chiesa C, Lindén O, Flux G. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur. J. Nucl. Med. Mol. Imaging 2010; 37:1238-1250.
  14. Kletting P, Kull T, Bunjes D, Mahren B, Luster M, Reske SN, Glatting G. Radioimmunotherapy with anti-CD66 antibody: Improving the biodistribution using a physiologically based pharmacokinetic model. J. Nucl. Med. 2010; 51:484-491.mit freundlicher Unterstützung der Deutschen José Carreras Leukämie-Stiftung e. V.
  15. Kletting P, Meyer C, Reske SN, Glatting G. Potential of optimal preloading in anti-CD20 antibody radioimmunotherapy: An investigation based on pharmacokinetic modeling. Cancer Biother. Radiopharm. 2010; 25:279-287.
  16. Kotzerke J, Oehme L, Lindner O, Hellwig D. Positron emission tomography 2008 in Germany - results of the query and current status. Nuklearmedizin 2010; 49:58-64.
  17. Lassmann M, Reiners C, Luster M. Dosimetry and thyroid cancer: the individual dosage of radioiodine. Endocr Relat Cancer 2010; 17:R161-172.
  18. Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, Glatting G, Buck AK, Solbach C, Neumaier B, Reske SN, Mottaghy FM. Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma. Eur J Nucl Med Mol Imaging 2010; 37:484-493.
  19. Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, Glatting G, Buck AK, Solbach C, Neumaier B, Reske SN, Mottaghy FM. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid 2010; 20:527-533.
  20. Luster M, Verburg FA, Scheidhauer K. Diagnostic imaging work up in multi-nodular goiter. Minerva Endocrinol 2010; 35:153-159.
  21. Luster M, Dietlein M. Wann Medikamente, wann Radiojod, wann Op.? Der Allgemeinarzt 2010; 13:1-8.
  22. Luster M. Die individualisierte Therapie des Schilddrüsenkarzinoms. Der Nuklearmediziner 2010; 33:201–202.
  23. Maier-Funk C, Weber T, Lang G, Hugl S, Reske SN, Luster M. Intrathoracic metastatic spread of parathyroid carcinoma. Nuklearmedizin 2010; 49:N62.
  24. Neumaier B, Deisenhofer S, Sommer C, Solbach C, Reske SN, Mottaghy F. Synthesis and evaluation of 18F-fluoroethylated benzothiazole derivatives for in vivo imaging of amyloid plaques in Alzheimer's disease. Appl. Radiat. Isot. 2010; 68:1066-1072.
  25. Salvatori M, Luster M. Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2010; 37:821-828.
  26. Schreyögg J, Weller J, Stargardt T, Herrmann K, Bluemel C, Dechow T, Glatting G, Krause BJ, Mottaghy F, Reske SN, Buck AK. Cost-Effectiveness of Hybrid PET/CT for Staging of Non-Small Cell Lung Cancer. J Nucl Med 2010; 51:1668-1675.
  27. Stokkel MP, Handkiewicz Junak D, Lassmann M, Dietlein M, Luster M. EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging 2010; 37:2218-2228.
  28. Verburg FA, Hänscheid H, Biko J, Hategan MC, Lassmann M, Kreissl MC, Reiners C, Luster M. Dosimetry-guided high-activity 131I therapy in patients with advanced differentiated thyroid carcinoma: initial experience. Eur J Nucl Med Mol Imag. 2010; 37:896-903.
  29. Verburg FA, Luster M. Low-risk differentiated thyroid carcinoma patients still deserve I-131 remnant ablation after total thyroidectomy. Minerva Chir 2010; 65:95-100.
  30. Verburg FA, Mader U, Kruitwagen CL, Luster M, Reiners C. A comparison of prognostic classification systems for differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2010; 72:830-838.
  31. Verburg FA, Stokkel MPM, Düren C, Verkooijen RBT, Mäder U, van Isselt JW, Marlowe RJ, Smit JW, Reiners C, Luster M. No survival difference after successful 131I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. Eur J Nucl Med Mol Imag 2010; 37:276-283.
  32. Weber T, Cammerer G, Schick C, Solbach C, Hillenbrand A, Barth TF, Henne-Bruns D, Blagieva R, Böhm BO, Reske SN, Luster M. C-11 methionine positron emission tomography/computed tomography localizes parathyroid adenomas in primary hyperparathyroidism. Horm Metab Res. 2010; 42:209-214.
  33. Weber YG, Roebling R, Kassubek J, Hoffmann S, Rosenbohm A, Wolf M, Steinbach P, Jurkat-Rott K, Walter H, Reske SN, Lehmann-Horn F, Mottaghy FM, Lerche H. Comparative analysis of brain structure, metabolism, and cognition in myotonic dystrophy 1 and 2. Neurology 2010; 74:1108-1117.